← Research library

Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion

Animal research · 2002

What was studied
Experimental myocardial reperfusion
Main finding
The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.

Reported findings and study design

Coronary-reperfusion experiment: Dalargin or DADLE 0.1 mg/kg immediately before reperfusion.

Population or model Experimental myocardial reperfusion

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Ventricular arrhythmiasPrevention reported
μ-receptor blockadeAbolished the antiarrhythmic effect

Numerical arrhythmia counts not supplied in the indexed abstract.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Preclinical model; no human treatment benefit established.
  • DADLE and Dalargin are distinct peptides.

Source details

Selected source text and metadata checked; full risk-of-bias review pending.

Selected text reviewed

Sources checked

Citation

Animal / experimentalEnglish abstract

Author unconfirmed. Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion Indexed original publication; PMID 12124638

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards